Bone metastases in advanced prostate cancer. Management

6/20/22, 12:19 AM 17128
2002; 94:1458.
35. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men
with castration-resistant prostate cancer: results of a phase 3, randomised, placebocontrolled
trial. Lancet 2012; 379:39.
36. Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in
men with castration-sensitive prostate cancer and bone metastases: results of CALGB
90202 (alliance). J Clin Oncol 2014; 32:1143.
37. Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with highrisk
nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results
of the Zometa European Study (ZEUS). Eur Urol 2015; 67:482.
38. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate
cancer--results of a randomized double-blind placebo-controlled trial: Medical Research
Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99:765.
39. Clarke NW. Balancing toxicity and efficacy: learning from trials and treatment using
antiresorptive therapy in prostate cancer. Eur Urol 2014; 65:287.
40. Gartrell BA, Coleman RE, Fizazi K, et al. Toxicities following treatment with bisphosphonates
and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced
prostate cancer. Eur Urol 2014; 65:278.
Topic 17128 Version 62.0
https://www.uptodate.com/contents/17128/print 20/27